Abstract
Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.
| Original language | English |
|---|---|
| Pages (from-to) | 421-425 |
| Number of pages | 5 |
| Journal | Pharmacological Research |
| Volume | 113 |
| DOIs | |
| Publication status | Published - Nov 1 2016 |
Fingerprint
Keywords
- AEDs
- GABA
- Hippocampal sclerosis
- MTLE
- Neuroinflammation
ASJC Scopus subject areas
- Pharmacology
Cite this
Pharmacological modulation in mesial temporal lobe epilepsy : Current status and future perspectives. / Gambardella, Antonio; Labate, Angelo; Cifelli, Pierangelo; Ruffolo, Gabriele; Mumoli, Laura; Aronica, Eleonora; Palma, Eleonora.
In: Pharmacological Research, Vol. 113, 01.11.2016, p. 421-425.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacological modulation in mesial temporal lobe epilepsy
T2 - Current status and future perspectives
AU - Gambardella, Antonio
AU - Labate, Angelo
AU - Cifelli, Pierangelo
AU - Ruffolo, Gabriele
AU - Mumoli, Laura
AU - Aronica, Eleonora
AU - Palma, Eleonora
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.
AB - Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.
KW - AEDs
KW - GABA
KW - Hippocampal sclerosis
KW - MTLE
KW - Neuroinflammation
UR - http://www.scopus.com/inward/record.url?scp=84988526089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988526089&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2016.09.019
DO - 10.1016/j.phrs.2016.09.019
M3 - Article
AN - SCOPUS:84988526089
VL - 113
SP - 421
EP - 425
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
ER -